• TMEM16F in Kupffer Cells Protects Against Listeria

  2026-09-02

  The reference study identifies Kupffer cell-expressed TMEM16F as a key determinant of host protection during Listeria monocytogenes infection, shifting the focus from lymphocytes to liver-resident macrophages. Its data connect calcium-activated lipid scrambling and plasma-membrane repair with control of liver inflammation, tissue injury, and metabolic disruption.

• Alda 1 for ALDH2 Activation in Cardiac Research

  2026-09-01

  Alda 1 provides a practical way to test how ALDH2 activation links aldehyde detoxification with cardiomyocyte survival and proliferation. This guide translates recent pressure-overload findings into assay-ready workflows for cardiac ischemia research, ALDH2 variant comparisons, and carefully bounded radiation studies.

• How GCG Disrupts SARS-CoV-2 N Condensation

  2026-08-31

  The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic feature of viral biology and shows that (-)-gallocatechin gallate disrupts this process. Its integrated sequence, biochemical, infection-associated, and replication analyses support viral condensates as a potential antiviral target, while also defining important limits for translation.

• O-propargyl-puromycin (OPP) for Protein Synthesis

  2026-08-31

  O-propargyl-puromycin (OPP) converts short translation pulses into measurable nascent-protein signals for imaging, flow cytometry, immunoblotting, and enrichment. Its most informative use is comparative: linking global translation changes to mitochondrial stress, B-cell differentiation, and proteome remodeling rather than relying on a single protein endpoint.

• (-)-JQ1: A Rigorous BET Control in AML Studies

  2026-08-30

  (-)-JQ1 is an inactive JQ1 stereoisomer that helps separate BET bromodomain-dependent biology from vehicle, stress, and compound-class effects. This workflow applies the control to BRD4 target gene modulation, inv(16) AML models, and translational epigenetics research without mistaking a negative control for a therapeutic agent.

• Angiotensin II Workflows for Vascular Research

  2026-08-29

  Build reproducible cell and animal workflows around Angiotensin II to model oxidative endothelial injury, vascular smooth muscle cell hypertrophy, hypertension signaling, and vascular remodeling. This guide combines product-specific handling parameters with a reference-informed HUVEC assay strategy and practical troubleshooting.

• S1P/S1PR3 Drives Neuronal Apoptosis After ICH

  2026-08-28

  A 2024 study identifies S1PR3 as a receptor-level driver of neuronal apoptosis after intracerebral hemorrhage, linking S1P signaling to TNF-α, PI3K/AKT, and caspase-3 activation. In vivo and cell-based findings suggest that S1PR3 antagonism may reduce secondary neuronal injury, while also highlighting the need for more selective and translational validation.

• Fosinopril Sodium: From ACE Mechanism to Translation

  2026-08-28

  A translational framework for using Fosinopril sodium in hypertension research, cardiovascular disease models, blood pressure reduction studies, and renal hemodynamics modulation—with attention to prodrug activation, exposure control, and clinically meaningful endpoints.

• Losartan Workflows for AT1 and TME Studies

  2026-08-28

  Use Losartan to connect angiotensin II receptor biology with vascular smooth muscle, fibroblast, and tumor-microenvironment assays. This workflow emphasizes receptor-aware dosing, collagen remodeling readouts, and controls that distinguish AT1 signaling from nonspecific cytotoxicity.

• FGF4-FGFR1 Signaling Protects Podocytes in DKD

  2026-08-27

  A 2025 Nature Communications study identifies podocyte-derived FGF4 as an endogenous protective factor in diabetic kidney disease. Using genetic loss-of-function, recombinant FGF4 rescue, diabetic mouse models, and high-glucose human podocytes, the authors connect FGF4-FGFR1 activity with AMPK-FOXO1 signaling, reduced oxidative stress, and improved glomerular function.

• ICAA Targets RIP3 in Cardiac Hypertrophy

  2026-08-27

  A 2026 Cellular Signalling study identifies isochlorogenic acid A as an inhibitor of RIP3 phosphorylation in angiotensin II- and pressure overload-induced cardiac hypertrophy. Its central mechanistic advance is the definition of a RIP3/CaMKII pathway that promotes hypertrophic remodeling independently of MLKL, providing a focused framework for cardiovascular disease research.

• WM-8014: KAT6A Inhibitor Workflow Guide

  2026-08-26

  WM-8014 offers a reversible, competitive way to interrogate KAT6A/B-dependent chromatin regulation without relying exclusively on genetic depletion. This guide translates its selectivity profile and the RESTRICT-seq findings into practical cell-cycle, senescence, resistance, and tumor-growth workflows, with safeguards against solubility, timing, and interpretation errors.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-08-26

  The 2024 Theranostics study identifies low PPP2R2A, which encodes the PP2A B55α regulatory subunit, as a potential biomarker for sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Its experiments connect PPP2R2A loss with c-Myc-driven replication stress, increased replication initiation, and CHK1 dependence, including in models resistant to PARP inhibition.

• miR-1268a, CD36, and Angiotensin II Heart Failure

  2026-08-25

  This 2024 study identifies miR-1268a as an inducible regulator of fatty-acid uptake, ATP production, and oxidative stress in Angiotensin II-treated AC16 cardiomyocytes. Its key contribution is linking miR-1268a to CD36, while also showing that miR-1268a inhibition partially reverses several cellular features of the in vitro heart-failure model.

• Pazopanib (GW-786034): RTK Mechanism & Research

  2026-08-24

  Pazopanib (GW-786034) is a multi-targeted receptor tyrosine kinase inhibitor that suppresses VEGFR, PDGFR, and FGFR signaling in cancer research models. Its strongest experimental value is mechanistic: it connects angiogenesis inhibition with receptor-dependent tumor growth suppression and ATRX-stratified glioma sensitivity.

452 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page